Mark S. Todtenkopf

Alkermes, Inc., USA 0000-0003-4764-7816

Mark S. Todtenkopf holds a B.S. degree in neuropsychology from the University of Massachusetts Amherst, Mass, USA, an M.A. in experimental psychology, and a Ph.D. degree in experimental psychology from Northeastern University, Boston, Mass, USA. After completing his Ph.D., he did his postdoctoral fellowship at Harvard Medical School and became an Instructor in psychiatry in 2004. His research focused on the neuroanatomical relationships between drugs of abuse and drug-related behaviors, as well as mechanisms underlying mood disorders such as depression and schizophrenia. In 2006, he joined Alkermes, Inc. in Waltham, Mass, USA, a biotechnology company focused on treating CNS disorders such as addiction, depression, and schizophrenia. Dr. Todtenkopf is currently a Senior Scientist II at the Life Sciences and Toxicology Department, conducting preclinical drug discovery and development studies focused in several areas, including addiction, opioid pharmacology, mood disorders, and several other areas of interest.

Biography Updated on 2 January 2013

Scholarly Contributions [Data Provided by scopus]

download